ArticleAmerican journal of cancer research2024

Genetic alterations predict poor efficacy, outcomes and resistance to second-line osimertinib treatment in non-small cell lung cancer.

Hao Bai et al.PubMed ↗Full text ↗

No numbers read from the abstract.